Ed Pratesi's Byline Featured on PharmExec.com - "Does the Pfizer Restructuring Make Sense?"

Pfizer recently announced a major restructuring into three business segments. The move followed an unsuccessful attempt by the company to market its OTC, or Consumer Healthcare segment as it will be named under the new regime. The reorganization will position the company’s most promising growth area as its rebranded Innovative Medicines segment with the existing business lines from the old segment, as well as adding biosimilars and a new hospital business unit.

The Established Medicine segment will include many of its legacy products, including Lipitor. Management indicates that this segment will operate as a standalone business and include drugs whose patent rights will expire soon along with other legacy products, as well as having its own dedicated manufacturing capabilities.

This article was originally published by PharmExec.com. Click here to read full article.

Categories: In the News

For More Information

Fill out our online form